Cargando…

Longitudinal tumor fraction trajectories predict risk of progression in metastatic HR(+) breast cancer patients undergoing CDK4/6 treatment

Despite improved clinical outcomes, intrinsic or acquired resistance to CDK4/6 inhibitor treatment has limited the success of this treatment in HR(+)HER2(−) metastatic breast cancer patients. Biomarkers are urgently needed, and longitudinal biomarker measurements may harbor more dynamic predictive a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dandachi, Nadia, Posch, Florian, Graf, Ricarda, Suppan, Christoph, Klocker, Eva Valentina, Müller, Hannah Deborah, Lindenmann, Jörg, Terbuch, Angelika, Heitzer, Ellen, Balic, Marija
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410553/ https://www.ncbi.nlm.nih.gov/pubmed/33264486 http://dx.doi.org/10.1002/1878-0261.12870

Ejemplares similares

Untargeted Assessment of Tumor Fractions in Plasma for Monitoring and Prognostication from Metastatic Breast Cancer Patients Undergoing Systemic Treatment
por: Suppan, Christoph, et al.
Publicado: (2019)

Primary patient-derived lung adenocarcinoma cell culture challenges the association of cancer stem cells with epithelial-to-mesenchymal transition
por: Tiran, Verena, et al.
Publicado: (2017)

Neutrophil/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy
por: Suppan, Christoph, et al.
Publicado: (2015)

Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity
por: Suppan, Christoph, et al.
Publicado: (2021)

Deciphering the molecular landscape of metastatic lobular breast cancer
por: Dandachi, Nadia, et al.
Publicado: (2022)

Genetic profiling of putative breast cancer stem cells from malignant pleural effusions
por: Tiran, Verena, et al.
Publicado: (2017)

Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy
por: Müller, Hannah Deborah, et al.
Publicado: (2019)

Genetic and epigenetic analysis of putative breast cancer stem cell models
por: Balic, Marija, et al.
Publicado: (2013)

Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer
por: Perakis, Samantha O, et al.
Publicado: (2020)

Chronic Oxidative Stress Promotes Molecular Changes Associated with Epithelial Mesenchymal Transition, NRF2, and Breast Cancer Stem Cell Phenotype
por: Čipak Gašparović, Ana, et al.
Publicado: (2019)

Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression
por: Brcic, Iva, et al.
Publicado: (2023)

Early stage breast cancer treatment and prognostic factors: Post San Antonio Breast Cancer Symposium 2016
por: Suppan, Christoph, et al.
Publicado: (2017)

It is time to prepare for D-CARE!
por: Suppan, Christoph, et al.
Publicado: (2020)

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
por: Zhou, Qing, et al.
Publicado: (2022)

Multigene methylation analysis of enriched circulating tumor cells associates with poor progression-free survival in metastatic breast cancer patients
por: Benezeder, Theresa, et al.
Publicado: (2017)

Hazard Curves for Tumor Recurrence and Tumor-Related Death Following Esophagectomy for Esophageal Cancer
por: Lindenmann, Joerg, et al.
Publicado: (2020)

Reflex testing in non-small cell lung carcinoma using DNA- and RNA-based next-generation sequencing—a single-center experience
por: Zacharias, Martin, et al.
Publicado: (2021)

Cellular senescence in the response of HR(+) breast cancer to radiotherapy and CDK4/6 inhibitors
por: Klapp, Vanessa, et al.
Publicado: (2023)

Next Generation Cancer Vaccines—Make It Personal!
por: Terbuch, Angelika, et al.
Publicado: (2018)

Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2− advanced breast cancer
por: Corona, Silvia Paola, et al.
Publicado: (2018)

Detection of AML-specific TP53 mutations in bone marrow–derived mesenchymal stromal cells cultured under hypoxia conditions
por: Müller, Marian, et al.
Publicado: (2019)

TP53 mutated AML subclones exhibit engraftment in a humanized bone marrow ossicle mouse model
por: Pabst, Gabriel, et al.
Publicado: (2020)

C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study
por: Riedl, Jakob M., et al.
Publicado: (2020)

The CDK4/6 inhibitor in HR-positive advanced breast cancer: A systematic review and meta-analysis
por: Ding, Wu, et al.
Publicado: (2018)

CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
por: Di Cosimo, Serena, et al.
Publicado: (2020)

Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer
por: Posch, Florian, et al.
Publicado: (2022)

Preoperative Peak Oxygen Consumption: A Predictor of Survival in Resected Lung Cancer
por: Lindenmann, Joerg, et al.
Publicado: (2020)

Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry‐based leukemic cell enrichment followed by mutational profiling
por: Daga, Shruti, et al.
Publicado: (2020)

The Interaction of CtIP and Nbs1 Connects CDK and ATM to Regulate HR–Mediated Double-Strand Break Repair
por: Wang, Hailong, et al.
Publicado: (2013)

CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?
por: Agostinetto, Elisa, et al.
Publicado: (2020)

HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
por: Sammons, Sarah L., et al.
Publicado: (2017)

ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer
por: Petrossian, Karineh, et al.
Publicado: (2018)

How to Treat HR+/HER2- Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
por: Cogliati, Viola, et al.
Publicado: (2022)

Are We Prepared for the CDK4/6 Revolution With HR+/HER2− Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies
por: Azoz, Seyla, et al.
Publicado: (2023)

HR TEAM
por: Brice, Maximilien
Publicado: (2015)

HR Organigramme
por: Favre, A
Publicado: (2001)

Organigramme HR
por: Favre, A
Publicado: (2011)

HR Explorer
por: Möller, M, et al.
Publicado: (1997)

Careers HR
por: Marcastel, Fabienne CERN Graphic Design service
Publicado: (2013)

Estimation versus measurement of the glomerular filtration rate for kidney function assessment in patients with cancer undergoing cisplatin-based chemotherapy
por: Klöckl, Marie-Christin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2m8mepq7iacc3e9rhdtbpomocl